Dosing instructions
Method of administration and Dosing1
Prevymis® is available both as a tablet and IV.
PREVYMIS® should be started after allo-HSCT. PREVYMIS® may be started on the day of transplant and no later than 28 days post-HSCT. PREVYMIS® may be started before or after engraftment. Prophylaxis with PREVYMIS® should continue through 100 days post-HSCT. Prolonged PREVYMIS® prophylaxis beyond 100 days post-HSCT may be of benefit in some patients at high risk for late CMV reactivation (see section 5.1). The safety and efficacy of PREVYMIS® use for more than 200 days has not been studied in clinical trials.
The recommended dose of PREVYMIS® is 480 mg once daily, and is both in tablet and concentrate for solution for infusion. Tablets and concentrate for solution for infusion may be used interchangeably at the discretion of the physician, and no dose adjustment is necessary.
Dose adjustment
If PREVYMIS® is co-administered with cyclosporine, the dose of PREVYMIS® should be decreased to 240 mg once daily (See section 4.5 and 5.2 in the SmPC for complete information on dose adjustment).
If cyclosporine is initiated after starting PREVYMIS®, the next dose of PREVYMIS® should be decreased to 240 mg once daily.
If cyclosporine is discontinued after starting PREVYMIS®, the next dose of PREVYMIS® should be increased to 480 mg once daily.
If cyclosporine dosing is temporarily interrupted due to high cyclosporine levels, no dose adjustment of PREVYMIS® is needed.
References:
- PREVYMIS®. Summary of product characteristics, April 2025.
